liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences.
Sichuan University, China.
Linköping University, Department of Clinical and Experimental Medicine, Oncology. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Oncology.
2013 (English)In: Tumor Biology, ISSN 1010-4283, E-ISSN 1423-0380, Vol. 34, no 2, 683-693 p.Article in journal (Refereed) Published
Abstract [en]

The antiapoptotic factor Livin has been considered critical for tumor progression and poor prognosis for variant types of tumors. However, there are only limited reports regarding its expression and biological functions in colon cancer. Here, we examined Livin expression in four colon cancer cell lines (HCT116, RKO, KM12C, and SW620) in the presence or absence of cisplatin that was used as a model reagent. We found the different response to cisplatin was related to endogenous Livin expression level. From among a panel of apoptosis-related factors (p53, Bcl-2, Bcl-XL, BAX, and survivin), the expression of Livin was upregulated after cisplatin treatment in a dose-dependent manner. Both immunocytochemistry and nuclear cytoplasmic fractionation indicated Livin remained in the cytoplasm after treatment with cisplatin. In an attempt to explore the mechanism, we found the elevated expression of Livin was not due to the decreased degradation by proteosome but was enhanced at the mRNA level. Besides, cisplatin treatment activated the mammalian target of rapamycin (mTOR) pathway as shown by increased phosphorylation of Akt1, mTOR, S6K, and 4E-BP1, together with the elevated Livin. The PI3K inhibitor LY294002 inhibited both the phosphorylation of mTOR and upregulation of Livin. The stable overexpression of Livin inhibited the activation of caspase-3 and led to resistance to cisplatin, while the knockdown of Livin by siRNA rendered colon cancer cells more sensitive to cisplatin. Our study, along with others, highlighted the potential of Livin for cancer therapy in colon cancer.

Place, publisher, year, edition, pages
Karger / Springer Verlag (Germany) , 2013. Vol. 34, no 2, 683-693 p.
Keyword [en]
Livin; Apoptosis; Cisplatin; Colon cancer
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-96160DOI: 10.1007/s13277-012-0596-8ISI: 000316364500010OAI: diva2:640710
Available from: 2013-08-14 Created: 2013-08-14 Last updated: 2013-08-27Bibliographically approved

Open Access in DiVA

fulltext(1516 kB)208 downloads
File information
File name FULLTEXT01.pdfFile size 1516 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Ding, Zhen-YuOlsson, BirgitSun, Xiao-Feng
By organisation
Department of Clinical and Experimental MedicineFaculty of Health SciencesOncologyDivision of Clinical SciencesDepartment of Oncology
In the same journal
Tumor Biology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 208 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 71 hits
ReferencesLink to record
Permanent link

Direct link